Literature DB >> 18452693

Complete atrioventricular block associated with concomitant use of metoprolol and paroxetine.

Orhan Onalan1, Birgul Elbozan Cumurcu, Lutfu Bekar.   

Abstract

A 63-year-old woman, who had been treated with 20 mg of paroxetine and 0.5 mg of alprazolam daily for 1 year and with 50 mg of metoprolol daily for 15 days, presented to a facility elsewhere with presyncope and complete atrioventricular block. Three days after her initial presentation and cessation of metoprolol treatment, she was transferred to our clinic to be considered for permanent pacemaker implantation. Paroxetine treatment was discontinued on day 1 and atrioventricular block resolved on day 5, which was confirmed with a 24-hour Holter recording. No bradyarrhythmia was induced with similar doses of either metoprolol or paroxetine alone. At 2- and 3-year follow-up, the patient was still free of bradyarrhythmia documented with electrocardiography and 24-hour Holter recordings. To our knowledge, we report the first case of complete atrioventricular block associated with coadministration of paroxetine and metoprolol. Increasing physicians' awareness of drug-induced severe bradyarrhythmia might prevent unnecessary implantation of permanent pacemakers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18452693     DOI: 10.4065/83.5.595

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  11 in total

Review 1.  Benefits and pitfalls of cardiovascular medication in seniors.

Authors:  Hana Matejovska Kubesova; Pavel Weber; Hana Meluzinova; Katarina Bielakova; Jan Matejovsky
Journal:  Wien Klin Wochenschr       Date:  2013-07-12       Impact factor: 1.704

2.  Extreme bradycardia due to multiple drug-drug interactions in a patient with HIV post-exposure prophylaxis containing lopinavir-ritonavir.

Authors:  Rachel Puech; Marie-Claude Gagnieu; Caroline Planus; Bruno Charpiat; André Boibieux; Tristan Ferry; Michel Tod
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

3.  Clinically important interaction between metoprolol and propafenone.

Authors:  Jana Duricova; Ilona Perinova; Nikola Jurckova; Ivana Kacirova; Milan Grundmann
Journal:  Can Fam Physician       Date:  2013-04       Impact factor: 3.275

4.  [Psychopharmacotherapy in patients with cardiovascular diseases].

Authors:  J Cordes; C Lange-Asschenfeldt; C Hiemke; K G Kahl
Journal:  Internist (Berl)       Date:  2012-11       Impact factor: 0.743

5.  Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine.

Authors:  Stephen M Stout; Jace Nielsen; Lynda S Welage; Michael Shea; Robert Brook; Kevin Kerber; Barry E Bleske
Journal:  J Clin Pharmacol       Date:  2010-04-16       Impact factor: 3.126

6.  Antidepressants, metoprolol and the risk of bradycardia.

Authors:  Paul A Kurdyak; Michael Manno; Tara Gomes; Muhammad M Mamdani; David N Juurlink
Journal:  Ther Adv Psychopharmacol       Date:  2012-04

7.  Cytochrome P450-2D6 Genotype Definition May Improve Therapy for Paroxysmal Atrial Fibrillation A Case of Syncope Following "Pill-in-the-Pocket" Quinidine plus Propafenone.

Authors:  Harry W Daniell M D
Journal:  J Atr Fibrillation       Date:  2014-02-28

8.  Discontinuation and dose adjustment of metoprolol after metoprolol-paroxetine/fluoxetine co-prescription in Dutch elderly.

Authors:  Muh Akbar Bahar; Yuanyuan Wang; Jens H J Bos; Bob Wilffert; Eelko Hak
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-03-24       Impact factor: 2.890

9.  Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross-Sectional Descriptive Study as Part of the PharmLines Initiative.

Authors:  Muh Akbar Bahar; Jens H J Bos; Sander D Borgsteede; Aafje Dotinga; Rolinde A Alingh; Bob Wilffert; Eelko Hak
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

10.  The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine.

Authors:  Muh Akbar Bahar; Jasper Kamp; Sander D Borgsteede; Eelko Hak; Bob Wilffert
Journal:  Br J Clin Pharmacol       Date:  2018-09-24       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.